NCT00892450

Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease

Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease: A Randomized, Double-blind, Crossover Pilot Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: US Department of Veterans Affairs · Federal
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to investigate the cognitive (thinking, memory, knowledge, intelligence) side effects of two medications commonly used to treat overactive bladder (OAB) symptoms in veteran patients with Parkinson's disease (PD) seen at the Philadelphia PADRECC.

Detailed description

This study will be a double-blinded cross-over clinical trial design to assess the prevalence of cognitive effects, the efficacy, and the effect on quality of life (QOL) of two anticholinergic medications commonly used in the treatment of overactive bladder (OAB): oxybutynin and darifenacin. This will be done by use of a well-established and validated computer-based cognitive battery. Secondary endpoints will assess efficacy of anticholinergic therapy on symptoms of OAB via QOL questionnaire and participant urinary diaries.

Conditions

• Parkinson's Disease
• Overactive Bladder

Interventions

Type	Name	Description
DRUG	Oxybutynin and darifenacin	Participants with overactive bladder will take each medication for 4 weeks.

Timeline

• Start date: 2009-05-01
• Primary completion: 2014-09-01
• Completion: 2014-09-01
• First posted: 2009-05-04
• Last updated: 2014-10-03

Locations

1 site across 1 country: United States